Efficacy of uterine artery embolization (UAE) for uterine fibroids according to FIGO classification: a single-center experience
Objective This study aims to retrospectively evaluate the outcomes of uterine artery embolization (UAE) for uterine fibroids (UFs), specifically submucosal UFs, according to the International Federation of Gynecology and Obstetrics (FIGO) classification of UFs. Materials and methods Forty-two patien...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of radiology 2024-02, Vol.42 (2), p.174-181 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 174 |
| container_title | Japanese journal of radiology |
| container_volume | 42 |
| creator | Ito, Hiroe Nakai, Motoki Yunaiyama, Daisuke Shirota, Natsuhiko Kobayashi, Takehiro Yasutomi, Mika Kikuchi, Takayuki Kinoshita, Yuta Takara, Yuki Tanaka, Taro Saguchi, Toru Saito, Kazuhiro |
| description | Objective
This study aims to retrospectively evaluate the outcomes of uterine artery embolization (UAE) for uterine fibroids (UFs), specifically submucosal UFs, according to the International Federation of Gynecology and Obstetrics (FIGO) classification of UFs.
Materials and methods
Forty-two patients with symptomatic UFs underwent UAE with Embosphere
®
between July 2016 and November 2021. MRI was performed before, at 3 and 6 months after the UAE. At each examination, the volume of UF was measured, and the percentage volume reduction rate (VRR) was calculated. The technical success rate (TSR), symptom improvement rate (SIR), regrowth rate (RR) after 6 months, and adverse events (AEs) were examined; VRR was compared between patients with submucosal UFs (FIGO types 0–2, group A), those with submucosal contacts (FIGO type 3, group B), and those without submucosal UFs (FIGO types 4–7, group C). Statistical analysis was performed on the difference in VRR between groups A, B, and C at 3 and 6 months after UAE. The relationship with hormone levels before UAE and VRR was evaluated.
Results
Thirty-seven of the 42 patients were evaluated. Overall, VRR was 37.0% at 3 months and 52.1% at 6 months; TSR, SIR, and RR were 100%, 95.2%, and 5.4%, respectively; VRR at 6 months was 80.7% for group A (
n
= 7), 57.8% for group B (
n
= 13), and 37.1% for group C (
n
= 17). Significant differences were found between A and C (
p
|
| doi_str_mv | 10.1007/s11604-023-01492-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2875381970</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918397095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-fdaa86258d03d94399fb380b1d17c7de66405e15fa0d70b25470fb6bd61d37bd3</originalsourceid><addsrcrecordid>eNp9kTtrHDEURkVIiB_JH0gRBGnsYhLd0Ywe7oxZP8DgJoZ0Qk8jMztaSzPgTZO_bq3X3oALV7pwz3d04UPoG5CfQAj_VQAY6RrS0oZAJ9sGPqB9EIw3QMSfj7uZwx46KOWeENbRrvuM9igX0DPZ76N_ixCi1XaNU8Dz5HMcPda5DmvslyYN8a-eYhrx0e3p4hiHlHdUiCan6ArW1qbs4niHp4TPry5usB10KXEj3mRPsMalrgffWD_WNPaPq-rwo_Vf0Kegh-K_vryH6PZ88fvssrm-ubg6O71uLJXt1ASntWBtLxyhTnZUymCoIAYccMudZ6wjvYc-aOI4MW3fcRIMM46Bo9w4eoiOtt5VTg-zL5NaxmL9MOjRp7moVvCeCpCcVPTHG_Q-zXms16lWgqCVkX2l2i1lcyol-6BWOS51XisgalOP2tajaj3quR4FNfT9RT2bpXe7yGsfFaBboNTVeOfz_7_f0T4BYtubWw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918397095</pqid></control><display><type>article</type><title>Efficacy of uterine artery embolization (UAE) for uterine fibroids according to FIGO classification: a single-center experience</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Ito, Hiroe ; Nakai, Motoki ; Yunaiyama, Daisuke ; Shirota, Natsuhiko ; Kobayashi, Takehiro ; Yasutomi, Mika ; Kikuchi, Takayuki ; Kinoshita, Yuta ; Takara, Yuki ; Tanaka, Taro ; Saguchi, Toru ; Saito, Kazuhiro</creator><creatorcontrib>Ito, Hiroe ; Nakai, Motoki ; Yunaiyama, Daisuke ; Shirota, Natsuhiko ; Kobayashi, Takehiro ; Yasutomi, Mika ; Kikuchi, Takayuki ; Kinoshita, Yuta ; Takara, Yuki ; Tanaka, Taro ; Saguchi, Toru ; Saito, Kazuhiro</creatorcontrib><description>Objective
This study aims to retrospectively evaluate the outcomes of uterine artery embolization (UAE) for uterine fibroids (UFs), specifically submucosal UFs, according to the International Federation of Gynecology and Obstetrics (FIGO) classification of UFs.
Materials and methods
Forty-two patients with symptomatic UFs underwent UAE with Embosphere
®
between July 2016 and November 2021. MRI was performed before, at 3 and 6 months after the UAE. At each examination, the volume of UF was measured, and the percentage volume reduction rate (VRR) was calculated. The technical success rate (TSR), symptom improvement rate (SIR), regrowth rate (RR) after 6 months, and adverse events (AEs) were examined; VRR was compared between patients with submucosal UFs (FIGO types 0–2, group A), those with submucosal contacts (FIGO type 3, group B), and those without submucosal UFs (FIGO types 4–7, group C). Statistical analysis was performed on the difference in VRR between groups A, B, and C at 3 and 6 months after UAE. The relationship with hormone levels before UAE and VRR was evaluated.
Results
Thirty-seven of the 42 patients were evaluated. Overall, VRR was 37.0% at 3 months and 52.1% at 6 months; TSR, SIR, and RR were 100%, 95.2%, and 5.4%, respectively; VRR at 6 months was 80.7% for group A (
n
= 7), 57.8% for group B (
n
= 13), and 37.1% for group C (
n
= 17). Significant differences were found between A and C (
p
< 0.001) and B and C (
p
= 0.023). Hormone levels before UAE had no effect on VRR. There was no significant AEs other than grade 3 pulmonary embolism in one patient.
Conclusion
UAE was effective for submucosal FIGO types 0–3. UAE was especially useful as an option for FIGO type 3 with a low protrusion rate that is difficult to treat with transcervical resection.</description><identifier>ISSN: 1867-1071</identifier><identifier>EISSN: 1867-108X</identifier><identifier>DOI: 10.1007/s11604-023-01492-1</identifier><identifier>PMID: 37815695</identifier><language>eng</language><publisher>Singapore: Springer Nature Singapore</publisher><subject>Classification ; Embolism ; Embolization ; Evaluation ; Female ; Fibroids ; Gynecology ; Hormones ; Humans ; Imaging ; Leiomyoma - diagnostic imaging ; Leiomyoma - therapy ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Obstetrics ; Original Article ; Pregnancy ; Radiology ; Radiotherapy ; Regrowth ; Retrospective Studies ; Statistical analysis ; Treatment Outcome ; Uterine Artery Embolization ; Uterine Neoplasms - therapy ; Uterus</subject><ispartof>Japanese journal of radiology, 2024-02, Vol.42 (2), p.174-181</ispartof><rights>The Author(s) under exclusive licence to Japan Radiological Society 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s) under exclusive licence to Japan Radiological Society.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c392t-fdaa86258d03d94399fb380b1d17c7de66405e15fa0d70b25470fb6bd61d37bd3</cites><orcidid>0000-0001-7300-6030</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11604-023-01492-1$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11604-023-01492-1$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37815695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ito, Hiroe</creatorcontrib><creatorcontrib>Nakai, Motoki</creatorcontrib><creatorcontrib>Yunaiyama, Daisuke</creatorcontrib><creatorcontrib>Shirota, Natsuhiko</creatorcontrib><creatorcontrib>Kobayashi, Takehiro</creatorcontrib><creatorcontrib>Yasutomi, Mika</creatorcontrib><creatorcontrib>Kikuchi, Takayuki</creatorcontrib><creatorcontrib>Kinoshita, Yuta</creatorcontrib><creatorcontrib>Takara, Yuki</creatorcontrib><creatorcontrib>Tanaka, Taro</creatorcontrib><creatorcontrib>Saguchi, Toru</creatorcontrib><creatorcontrib>Saito, Kazuhiro</creatorcontrib><title>Efficacy of uterine artery embolization (UAE) for uterine fibroids according to FIGO classification: a single-center experience</title><title>Japanese journal of radiology</title><addtitle>Jpn J Radiol</addtitle><addtitle>Jpn J Radiol</addtitle><description>Objective
This study aims to retrospectively evaluate the outcomes of uterine artery embolization (UAE) for uterine fibroids (UFs), specifically submucosal UFs, according to the International Federation of Gynecology and Obstetrics (FIGO) classification of UFs.
Materials and methods
Forty-two patients with symptomatic UFs underwent UAE with Embosphere
®
between July 2016 and November 2021. MRI was performed before, at 3 and 6 months after the UAE. At each examination, the volume of UF was measured, and the percentage volume reduction rate (VRR) was calculated. The technical success rate (TSR), symptom improvement rate (SIR), regrowth rate (RR) after 6 months, and adverse events (AEs) were examined; VRR was compared between patients with submucosal UFs (FIGO types 0–2, group A), those with submucosal contacts (FIGO type 3, group B), and those without submucosal UFs (FIGO types 4–7, group C). Statistical analysis was performed on the difference in VRR between groups A, B, and C at 3 and 6 months after UAE. The relationship with hormone levels before UAE and VRR was evaluated.
Results
Thirty-seven of the 42 patients were evaluated. Overall, VRR was 37.0% at 3 months and 52.1% at 6 months; TSR, SIR, and RR were 100%, 95.2%, and 5.4%, respectively; VRR at 6 months was 80.7% for group A (
n
= 7), 57.8% for group B (
n
= 13), and 37.1% for group C (
n
= 17). Significant differences were found between A and C (
p
< 0.001) and B and C (
p
= 0.023). Hormone levels before UAE had no effect on VRR. There was no significant AEs other than grade 3 pulmonary embolism in one patient.
Conclusion
UAE was effective for submucosal FIGO types 0–3. UAE was especially useful as an option for FIGO type 3 with a low protrusion rate that is difficult to treat with transcervical resection.</description><subject>Classification</subject><subject>Embolism</subject><subject>Embolization</subject><subject>Evaluation</subject><subject>Female</subject><subject>Fibroids</subject><subject>Gynecology</subject><subject>Hormones</subject><subject>Humans</subject><subject>Imaging</subject><subject>Leiomyoma - diagnostic imaging</subject><subject>Leiomyoma - therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Obstetrics</subject><subject>Original Article</subject><subject>Pregnancy</subject><subject>Radiology</subject><subject>Radiotherapy</subject><subject>Regrowth</subject><subject>Retrospective Studies</subject><subject>Statistical analysis</subject><subject>Treatment Outcome</subject><subject>Uterine Artery Embolization</subject><subject>Uterine Neoplasms - therapy</subject><subject>Uterus</subject><issn>1867-1071</issn><issn>1867-108X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kTtrHDEURkVIiB_JH0gRBGnsYhLd0Ywe7oxZP8DgJoZ0Qk8jMztaSzPgTZO_bq3X3oALV7pwz3d04UPoG5CfQAj_VQAY6RrS0oZAJ9sGPqB9EIw3QMSfj7uZwx46KOWeENbRrvuM9igX0DPZ76N_ixCi1XaNU8Dz5HMcPda5DmvslyYN8a-eYhrx0e3p4hiHlHdUiCan6ArW1qbs4niHp4TPry5usB10KXEj3mRPsMalrgffWD_WNPaPq-rwo_Vf0Kegh-K_vryH6PZ88fvssrm-ubg6O71uLJXt1ASntWBtLxyhTnZUymCoIAYccMudZ6wjvYc-aOI4MW3fcRIMM46Bo9w4eoiOtt5VTg-zL5NaxmL9MOjRp7moVvCeCpCcVPTHG_Q-zXms16lWgqCVkX2l2i1lcyol-6BWOS51XisgalOP2tajaj3quR4FNfT9RT2bpXe7yGsfFaBboNTVeOfz_7_f0T4BYtubWw</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Ito, Hiroe</creator><creator>Nakai, Motoki</creator><creator>Yunaiyama, Daisuke</creator><creator>Shirota, Natsuhiko</creator><creator>Kobayashi, Takehiro</creator><creator>Yasutomi, Mika</creator><creator>Kikuchi, Takayuki</creator><creator>Kinoshita, Yuta</creator><creator>Takara, Yuki</creator><creator>Tanaka, Taro</creator><creator>Saguchi, Toru</creator><creator>Saito, Kazuhiro</creator><general>Springer Nature Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7300-6030</orcidid></search><sort><creationdate>20240201</creationdate><title>Efficacy of uterine artery embolization (UAE) for uterine fibroids according to FIGO classification: a single-center experience</title><author>Ito, Hiroe ; Nakai, Motoki ; Yunaiyama, Daisuke ; Shirota, Natsuhiko ; Kobayashi, Takehiro ; Yasutomi, Mika ; Kikuchi, Takayuki ; Kinoshita, Yuta ; Takara, Yuki ; Tanaka, Taro ; Saguchi, Toru ; Saito, Kazuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-fdaa86258d03d94399fb380b1d17c7de66405e15fa0d70b25470fb6bd61d37bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Classification</topic><topic>Embolism</topic><topic>Embolization</topic><topic>Evaluation</topic><topic>Female</topic><topic>Fibroids</topic><topic>Gynecology</topic><topic>Hormones</topic><topic>Humans</topic><topic>Imaging</topic><topic>Leiomyoma - diagnostic imaging</topic><topic>Leiomyoma - therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Obstetrics</topic><topic>Original Article</topic><topic>Pregnancy</topic><topic>Radiology</topic><topic>Radiotherapy</topic><topic>Regrowth</topic><topic>Retrospective Studies</topic><topic>Statistical analysis</topic><topic>Treatment Outcome</topic><topic>Uterine Artery Embolization</topic><topic>Uterine Neoplasms - therapy</topic><topic>Uterus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ito, Hiroe</creatorcontrib><creatorcontrib>Nakai, Motoki</creatorcontrib><creatorcontrib>Yunaiyama, Daisuke</creatorcontrib><creatorcontrib>Shirota, Natsuhiko</creatorcontrib><creatorcontrib>Kobayashi, Takehiro</creatorcontrib><creatorcontrib>Yasutomi, Mika</creatorcontrib><creatorcontrib>Kikuchi, Takayuki</creatorcontrib><creatorcontrib>Kinoshita, Yuta</creatorcontrib><creatorcontrib>Takara, Yuki</creatorcontrib><creatorcontrib>Tanaka, Taro</creatorcontrib><creatorcontrib>Saguchi, Toru</creatorcontrib><creatorcontrib>Saito, Kazuhiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection (ProQuest)</collection><collection>Natural Science Collection (ProQuest)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of radiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ito, Hiroe</au><au>Nakai, Motoki</au><au>Yunaiyama, Daisuke</au><au>Shirota, Natsuhiko</au><au>Kobayashi, Takehiro</au><au>Yasutomi, Mika</au><au>Kikuchi, Takayuki</au><au>Kinoshita, Yuta</au><au>Takara, Yuki</au><au>Tanaka, Taro</au><au>Saguchi, Toru</au><au>Saito, Kazuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of uterine artery embolization (UAE) for uterine fibroids according to FIGO classification: a single-center experience</atitle><jtitle>Japanese journal of radiology</jtitle><stitle>Jpn J Radiol</stitle><addtitle>Jpn J Radiol</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>42</volume><issue>2</issue><spage>174</spage><epage>181</epage><pages>174-181</pages><issn>1867-1071</issn><eissn>1867-108X</eissn><abstract>Objective
This study aims to retrospectively evaluate the outcomes of uterine artery embolization (UAE) for uterine fibroids (UFs), specifically submucosal UFs, according to the International Federation of Gynecology and Obstetrics (FIGO) classification of UFs.
Materials and methods
Forty-two patients with symptomatic UFs underwent UAE with Embosphere
®
between July 2016 and November 2021. MRI was performed before, at 3 and 6 months after the UAE. At each examination, the volume of UF was measured, and the percentage volume reduction rate (VRR) was calculated. The technical success rate (TSR), symptom improvement rate (SIR), regrowth rate (RR) after 6 months, and adverse events (AEs) were examined; VRR was compared between patients with submucosal UFs (FIGO types 0–2, group A), those with submucosal contacts (FIGO type 3, group B), and those without submucosal UFs (FIGO types 4–7, group C). Statistical analysis was performed on the difference in VRR between groups A, B, and C at 3 and 6 months after UAE. The relationship with hormone levels before UAE and VRR was evaluated.
Results
Thirty-seven of the 42 patients were evaluated. Overall, VRR was 37.0% at 3 months and 52.1% at 6 months; TSR, SIR, and RR were 100%, 95.2%, and 5.4%, respectively; VRR at 6 months was 80.7% for group A (
n
= 7), 57.8% for group B (
n
= 13), and 37.1% for group C (
n
= 17). Significant differences were found between A and C (
p
< 0.001) and B and C (
p
= 0.023). Hormone levels before UAE had no effect on VRR. There was no significant AEs other than grade 3 pulmonary embolism in one patient.
Conclusion
UAE was effective for submucosal FIGO types 0–3. UAE was especially useful as an option for FIGO type 3 with a low protrusion rate that is difficult to treat with transcervical resection.</abstract><cop>Singapore</cop><pub>Springer Nature Singapore</pub><pmid>37815695</pmid><doi>10.1007/s11604-023-01492-1</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7300-6030</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1867-1071 |
| ispartof | Japanese journal of radiology, 2024-02, Vol.42 (2), p.174-181 |
| issn | 1867-1071 1867-108X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2875381970 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Classification Embolism Embolization Evaluation Female Fibroids Gynecology Hormones Humans Imaging Leiomyoma - diagnostic imaging Leiomyoma - therapy Medicine Medicine & Public Health Nuclear Medicine Obstetrics Original Article Pregnancy Radiology Radiotherapy Regrowth Retrospective Studies Statistical analysis Treatment Outcome Uterine Artery Embolization Uterine Neoplasms - therapy Uterus |
| title | Efficacy of uterine artery embolization (UAE) for uterine fibroids according to FIGO classification: a single-center experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T17%3A35%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20uterine%20artery%20embolization%20(UAE)%20for%20uterine%20fibroids%20according%20to%20FIGO%20classification:%20a%20single-center%20experience&rft.jtitle=Japanese%20journal%20of%20radiology&rft.au=Ito,%20Hiroe&rft.date=2024-02-01&rft.volume=42&rft.issue=2&rft.spage=174&rft.epage=181&rft.pages=174-181&rft.issn=1867-1071&rft.eissn=1867-108X&rft_id=info:doi/10.1007/s11604-023-01492-1&rft_dat=%3Cproquest_cross%3E2918397095%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2918397095&rft_id=info:pmid/37815695&rfr_iscdi=true |